TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2487696

Group type: EXPERIMENTAL
Intervention: Rest group (n=27 joints)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-rest group (n=36 joints)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups at later follow-up (average 10 months)
Number of subjects: 30
Study: 344007

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol (0.2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29913280

Group type: EXPERIMENTAL
Intervention: Emricasan (25 mg, twice daily for 3 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29393289

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Direct lateral interbody fusion (DLIF)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Both TLIF and DLIF
Number of subjects: 209
Study: 26331434

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) combined with intravenous patient-controlled sufentanil analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil alone (Control group)
Number of subjects: 60
Study: 23215545

Group type: EXPERIMENTAL
Intervention: Filtek SupremeXT (FSXT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tetric Evo Ceram (TEC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AELITE Aesthetic (AA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Estenia (E)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tescera ATL (TATL)
Number of subjects: 54
Study: 20561672

Group type: EXPERIMENTAL
Intervention: Referral via systematic identification through a brief mental health screening procedure
Number of subjects: 656

Group type: COMPARATOR
Intervention: Usual process of identification by school personnel, parents, or students themselves
Number of subjects: 656
Study: 19138370

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (200 mcg initially, then 300 mcg or 100 mcg based on responsiveness)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (200 mcg initially, then adjusted)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream
Number of subjects: 1161
Study: 17006735

Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sonographic gel application (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 62
Study: 15109503

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11313669

Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (10 g/m²), etoposide (900 mg/m²), and G-CSF (5 microg/kg twice a day) followed by autologous stem cell transplantation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (10 g/m²), mitoxantrone (20 mg/m²), and G-CSF (5 microg/kg) for patients with partial remission
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation using BEAM conditioning for patients achieving complete remission
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison with MINE-ESHAP salvage regimen
Number of subjects: 44
Study: 9043455

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 0
Study: 8180097

Group type: EXPERIMENTAL
Intervention: Philips TL12 tubes (0.8 to 3.3 kJ/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Philips TL01 tubes (3.1 to 18.6 kJ/m2)
Number of subjects: 17
Study: 30149126

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25943647

Group type: EXPERIMENTAL
Intervention: 400 µg Folic Acid (FA) daily for a median of 23 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: B-complex (400 µg FA, 10 µg cyanocob(III)alamin, and 8 mg pyridoxine) daily for a median of 23 days
Number of subjects: 58
Study: 25089513

Group type: EXPERIMENTAL
Intervention: Cognitive Narrative Psychotherapy (CNP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy (CBP)
Number of subjects: 97
Study: 23424889

Group type: EXPERIMENTAL
Intervention: Praziquantel + iron
Number of subjects: 406

Group type: COMPARATOR
Intervention: Praziquantel alone
Number of subjects: 406
Study: 20451683

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3153

Group type: COMPARATOR
Intervention: Unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: Baseline anemia
Number of subjects: 3153
Study: 19333040

Group type: EXPERIMENTAL
Intervention: Stoma group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonstoma group
Number of subjects: 34
Study: 16205779

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15663559

Group type: EXPERIMENTAL
Intervention: Dietary egg exclusion during pregnancy and lactation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified healthy diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cord OVA IgG concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cord IgG concentrations
Number of subjects: 0
Study: 10791109

Group type: EXPERIMENTAL
Intervention: IL-4 soluble receptor (IL-4sR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Other soluble cytokine receptors (IL-6sR, IL-1 beta, TNF-alpha, IL-1sR2, TNF-sR1, TNF-sR2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 9340503

Group type: EXPERIMENTAL
Intervention: Reteplase (10 MU in two bolus doses given 30 minutes apart)
Number of subjects: 15059

Group type: COMPARATOR
Intervention: Alteplase (up to 100 mg infused over a period of 90 minutes)
Number of subjects: 15059

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 15059

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 15059
Study: 8322987

Group type: EXPERIMENTAL
Intervention: Alfentanil (7 micrograms.kg‐1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 53
Study: 3089048

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 39
Study: 29527682

Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention involving video modelling, therapist- and peer-mediation and free play over 10 sessions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 10
Study: 27543164

Group type: EXPERIMENTAL
Intervention: Happy Quit (mobile phone-based text message interventions)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (text messages unrelated to quitting)
Number of subjects: 2000
Study: 23983272

Group type: EXPERIMENTAL
Intervention: Exercise training (cycle and strength training on 3 non-consecutive days per week for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 34
Study: 22855277

Group type: EXPERIMENTAL
Intervention: Moderate-exercise (MOD; 300 kcal/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-exercise (HIGH; 600 kcal/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 61
Study: 20472116

Group type: EXPERIMENTAL
Intervention: celecoxib 400 mg orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 18757090

Group type: EXPERIMENTAL
Intervention: n-3 PUFA 1 g daily
Number of subjects: 6975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6975
Study: 15777417

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 15
Study: 12003461

Group type: EXPERIMENTAL
Intervention: Diet condition (anticipated food deprivation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-diet condition (control)
Number of subjects: 0
Study: 10709595

Group type: EXPERIMENTAL
Intervention: Staged operations
Number of subjects: 15
Study: 7560238

Group type: EXPERIMENTAL
Intervention: Metronidazole impregnated collagen as a GTR membrane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain collagen barrier as control
Number of subjects: 16
Study: 1950723

Group type: EXPERIMENTAL
Intervention: Yuzpe method (ethinylestradiol 100 micrograms/levonorgestrel 500 micrograms repeated after 12 hours)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Danazol 600 mg repeated after 12 hours
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: RU486 600 mg single dose
Number of subjects: 215
Study: 7229228

Group type: EXPERIMENTAL
Intervention: Theophylline (6.5 +/- 0.9 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30230041

Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 18
Study: 28528804

Group type: EXPERIMENTAL
Intervention: Exergame group (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 38
Study: 26368562

Group type: EXPERIMENTAL
Intervention: Bowel preparation in LGIB patients
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Colonoscopy in LGIB patients
Number of subjects: 161
Study: 23418922

Group type: EXPERIMENTAL
Intervention: Rigid thoracoscopy (Olympus EndoEYE WA50120A, forceps)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Semi-rigid thoracoscopy (Olympus LTF-160, FB-55CR-1 forceps)
Number of subjects: 84
Study: 20580779

Group type: EXPERIMENTAL
Intervention: Almond diet
Number of subjects: 20
Study: 19808459

Group type: EXPERIMENTAL
Intervention: Burst antitachycardia pacing (ATP)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ramp antitachycardia pacing (ATP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both ATP strategies
Number of subjects: 206
Study: 17581288

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injections
Number of subjects: 0
Study: 14979758

Group type: EXPERIMENTAL
Intervention: Patterns of dependence and independence in causal inference (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex patterns of conditional dependencies (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence about patterns of dependence and independence (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional probabilities (Experiments 4 and 5)
Number of subjects: 0
Study: 12243664

Group type: EXPERIMENTAL
Intervention: Combined cryotherapy and triamcinolone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intralesional corticosteroid alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 10
Study: 9013304

Group type: EXPERIMENTAL
Intervention: Intraperitoneal insemination (IPI)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 205
Study: 8046781

Group type: EXPERIMENTAL
Intervention: Manidipine hydrochloride (MH)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nifedipine hydrochloride retard
Number of subjects: 63
Study: 2881414

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30249416

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 22
Study: 28228424

Group type: EXPERIMENTAL
Intervention: Diet soda containing sucralose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carbonated water (control)
Number of subjects: 18
Study: 25575743

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA)
Number of subjects: 40
Study: 23102741

Group type: EXPERIMENTAL
Intervention: tPA (tissue plasminogen activator)
Number of subjects: 624
Study: 20423740

Group type: EXPERIMENTAL
Intervention: Sibutramine plus L-carnitine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 254
Study: 18692323

Group type: EXPERIMENTAL
Intervention: High mammographic breast density (MBD) (>/=75% density)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MBD in the greatest quartile
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Obesity (body mass index, >/=30 kg/m(2))
Number of subjects: 136
Study: 17631452

Group type: EXPERIMENTAL
Intervention: Cardiac cell therapy using adult stem cells (muscular or bone marrow-derived)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embryonic stem cells
Number of subjects: 0
Study: 15153208

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Group R, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% lidocaine (Group L, n = 10)
Number of subjects: 30
Study: 12161083

Group type: EXPERIMENTAL
Intervention: Different methods of multidimensional screening
Number of subjects: 30000
Study: 9482768

Group type: EXPERIMENTAL
Intervention: 30 g maltitol in chocolate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 g maltitol in chocolate
Number of subjects: 20
Study: 8032307

Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene care (INT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Limited oral hygiene care (LIM)
Number of subjects: 150
Study: 2686416

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg intravenously every 12 hours
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ceftazidime 2 g intravenously every eight hours
Number of subjects: 113
Study: 31334795

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (n=581) - continuous intravenous insulin targeting blood glucose concentration of 80-130 mg/dL (4.4-7.2 mmol/L)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Standard treatment group (n=570) - insulin on a sliding scale targeting blood glucose concentration of 80-179 mg/dL (4.4-9.9 mmol/L)
Number of subjects: 1151
Study: 28911684

Group type: EXPERIMENTAL
Intervention: ANKASCIN 568 plus capsules (2 capsules daily for 12 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 2 capsules daily for 12 weeks)
Number of subjects: 39
Study: 26315684

Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with ketoconazole
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with carbamazepine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER with alprazolam XR
Number of subjects: 98
Study: 24429155

Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (MgSO4) 2.5 mL (250 mmol/L; 151 mg per dose)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) 2.5 mL
Number of subjects: 508
Study: 20598640

Group type: EXPERIMENTAL
Intervention: Hypospadics
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal infant boys
Number of subjects: 21
Study: 19958427

Group type: EXPERIMENTAL
Intervention: LHA shampoo (0.1% lipohydroxy acid and 1.3% salicylic acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CPO shampoo (1.5% ciclopiroxolamine, 3% salicylic acid, and 0.5% menthol)
Number of subjects: 100
Study: 17602064

Group type: EXPERIMENTAL
Intervention: Darbepoetin 150 microg/week, doubled if hemoglobin did not increase by >1 g/dl after 4 weeks
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Darbepoetin treatment
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination of sTfR after 2 weeks and hemoglobin after 4 weeks
Number of subjects: 196
Study: 14988450

Group type: EXPERIMENTAL
Intervention: 500 micro g FA capsule
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500 micro g [6S]-5-MTHF capsule
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 13
Study: 11253418

Group type: EXPERIMENTAL
Intervention: Viewing of a humor video for 1 hour
Number of subjects: 52
Study: 9490256

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 35

Group type: COMPARATOR
Intervention: i.m. morphine
Number of subjects: 35
Study: 7880151

Group type: EXPERIMENTAL
Intervention: Eating 100g hilsa fish per day for 10 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what they consumed)
Number of subjects: 0
Study: 2500561

Group type: EXPERIMENTAL
Intervention: TPN with carbohydrate and fat emulsion (FAT group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: TPN with only carbohydrate (non‐FAT group)
Number of subjects: 68
Study: 5540117

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31026118

Group type: EXPERIMENTAL
Intervention: ADC predictors added to standard functional tumor volume MRI
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ADC predictors for HR+/HER2-
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ADC predictors for HR+/HER2+
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ADC predictors for triple-negative breast cancer
Number of subjects: 415
Study: 27771276

Group type: EXPERIMENTAL
Intervention: Plaque HD (plaque-identifying toothpaste)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 61
Study: 25406267

Group type: EXPERIMENTAL
Intervention: Treadmill-only supervised exercise training for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Combination of treadmill and lower-limb resistance supervised exercise training for 12 weeks
Number of subjects: 35
Study: 22898999

Group type: EXPERIMENTAL
Intervention: 42 °C water immersion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cognitive functioning tasks during 42 °C condition
Number of subjects: 11

Group type: COMPARATOR
Intervention: 38 °C and 40 °C water immersion
Number of subjects: 11
Study: 16785375

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate PDT (160 mg/g; n = 96)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Cryotherapy (n = 82)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Fluorouracil (5% cream; n = 30)
Number of subjects: 225
Study: 12690029

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bedsheets (shukas)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 472
Study: 10519330

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + GnRH analogue
Number of subjects: 46

Group type: COMPARATOR
Intervention: GnRH analogue
Number of subjects: 46
Study: 7794710

Group type: EXPERIMENTAL
Intervention: Gentamicin (10 infants, group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Netilmicin (10 infants, group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amikacin (10 infants, group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (10 infection-free premature infants)
Number of subjects: 30
Study: 1826281

Group type: EXPERIMENTAL
Intervention: Human albumin infusion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hemaccel infusion
Number of subjects: 54
Study: 6754328

Group type: EXPERIMENTAL
Intervention: Factor XIII treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no factor XIII treatment)
Number of subjects: 60
Study: 30670277

Group type: EXPERIMENTAL
Intervention: Frankincense (300 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ginger (300 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 28704681

Group type: EXPERIMENTAL
Intervention: Rigid spineboard
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soft-layered spineboard
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both spineboards
Number of subjects: 12
Study: 25577973

Group type: EXPERIMENTAL
Intervention: Norepinephrine-low volume group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (liberal hydration)
Number of subjects: 163
Study: 23291728

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Change in galectin-3 levels over time
Number of subjects: 1650
Study: 21338550

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention (n = 67)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care (n = 62)
Number of subjects: 129
Study: 19050192

Group type: COMPARATOR
Intervention: 0 drinks per day
Number of subjects: 34715

Group type: EXPERIMENTAL
Intervention: > 0 and < 1 drinks per day
Number of subjects: 34715

Group type: EXPERIMENTAL
Intervention: >= 1 and < 2 drinks per day
Number of subjects: 34715

Group type: EXPERIMENTAL
Intervention: >= 2 drinks per day
Number of subjects: 34715
Study: 15914074

Group type: EXPERIMENTAL
Intervention: Mobilization-with-movement (MWM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (pooled data)
Number of subjects: 24
Study: 12823598

Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with ketoprofen (3 million units three times a week and 150 mg twice a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interferon-alpha alone (3 million units three times a week)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with ketoprofen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 80
Study: 10652067

Group type: EXPERIMENTAL
Intervention: Keller Plan (KP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 8701478

Group type: EXPERIMENTAL
Intervention: Oxybutynin (n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (n = 11)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Indomethacin (n = 9)
Number of subjects: 29
Study: 1833898

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 40
Study: 6137786

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45